Literature DB >> 19183344

Robust quantitative trait association tests in the parent-offspring triad design: conditional likelihood-based approaches.

J-Y Wang1, J J Tai.   

Abstract

Association studies, based on either population data or familial data, have been widely applied to mapping of genes underlying complex diseases. In family-based association studies, using case-parent triad families, the popularly used transmission/disequilibrium test (TDT) was proposed for avoidance of spurious association results caused by other confounders such as population stratification. Originally, the TDT was developed for analysis of binary disease data. Extending it to allow for quantitative trait analysis of complex diseases and for robust analysis of binary diseases against the uncertainty of mode of inheritance has been thoroughly discussed. Nevertheless, studies on robust analysis of quantitative traits for complex diseases received relatively less attention. In this paper, we use parent-offspring triad families to demonstrate the feasibility of establishment of the robust candidate-gene association tests for quantitative traits. We first introduce the score statistics from the conditional likelihoods based on parent-offspring triad data under various genetic models. By applying two existing robust procedures we then construct the robust association tests for analysis of quantitative traits. Simulations are conducted to evaluate empirical type I error rates and powers of the proposed robust tests. The results show that these robust association tests do exhibit robustness against the effect of misspecification of the underlying genetic model on testing powers.

Mesh:

Year:  2009        PMID: 19183344     DOI: 10.1111/j.1469-1809.2008.00502.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  8 in total

1.  Identification of an apoptosis-related prognostic gene signature and molecular subtypes of clear cell renal cell carcinoma (ccRCC).

Authors:  Weimin Zhong; Fengling Zhang; Chaoqun Huang; Yao Lin; Jiyi Huang
Journal:  J Cancer       Date:  2021-04-02       Impact factor: 4.207

2.  A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy.

Authors:  Pu Cheng; Zhen Wang; Guoming Hu; Qi Huang; Mengjiao Han; Jian Huang
Journal:  Oncotarget       Date:  2017-10-17

3.  Identification and validation of a prognostic 9-genes expression signature for gastric cancer.

Authors:  Zhiqiang Wang; Gongxing Chen; Qilong Wang; Wei Lu; Meidong Xu
Journal:  Oncotarget       Date:  2017-05-10

4.  A Prognostic 5-lncRNA Expression Signature for Head and Neck Squamous Cell Carcinoma.

Authors:  Guancheng Liu; Jinyang Zheng; Liming Zhuang; Yunxia Lv; Gangcai Zhu; Leiming Pi; Junchen Wang; Changhan Chen; Zhexuan Li; Jiangyi Liu; Liangjuan Chen; Gengming Cai; Xin Zhang
Journal:  Sci Rep       Date:  2018-10-15       Impact factor: 4.379

5.  A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma.

Authors:  Ze Gao; Dong Zhang; Yi Duan; Lei Yan; Yidong Fan; Zhiqing Fang; Zhaoxu Liu
Journal:  PLoS One       Date:  2019-03-01       Impact factor: 3.240

6.  14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients.

Authors:  Hong-Ye Jiang; Gang Ning; Yen-Sheng Wang; Wei-Biao Lv
Journal:  Biomed Res Int       Date:  2020-01-08       Impact factor: 3.411

7.  Identification and Validation of a Novel Prognostic Gene Model for Colorectal Cancer.

Authors:  Yan Meng; Rulin Zhou; Zhizhao Lin; Qun Peng; Jian Ding; Mei Huang; Yiwen Li; Xuxue Guo; Kangmin Zhuang
Journal:  Comput Math Methods Med       Date:  2022-07-25       Impact factor: 2.809

8.  Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.

Authors:  Yutao Wang; Kexin Yan; Jiaxing Lin; Jianfeng Wang; Zhenhua Zheng; Xinxin Li; Zhixiong Hua; Yuepeng Bu; Jianxiu Shi; Siqing Sun; Xuejie Li; Yang Liu; Jianbin Bi
Journal:  Aging (Albany NY)       Date:  2020-11-05       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.